ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

16 Tips from 16 Years Sick

Fibromyalgia Fare Fit for All Seasons

New Study Shows Artificial Sweeteners Lead to Diabetes

Essential Oils — An Effective and Healthy Option to Treat Headaches

Higher vitamin D levels associated with less severe disease in NAFLD patients

Krill Oil: Make This Omega-3 Supplement Part of Your Health Regimen

How zinc helps fight esophageal cancer

Everything You Need to Know About Black Cohosh

Low vitamin D levels predict ED in diabetics

The Cellular Enzyme That Promotes Longevity And Reduces Fat Storage

 
Print Page
Email Article

Protein Holds Promise as New Diabetes Drug Target

  [ 58 votes ]   [ Discuss This Article ]
www.ProHealth.com • July 18, 2003


Basic science, decades in the works, pays off in discovery
Scientists at the pharmaceutical company Hoffman-La Roche have discovered a chemical compound that activates the glucokinase enzyme and that could lead to a new medication for type 2 diabetes. Their work, reported in the July 18 issue of Science, builds on basic science performed at Vanderbilt University Medical Center that started 18 years ago.

When Dr. Mark A. Magnuson arrived at Vanderbilt in 1985 as a postdoctoral fellow, he took on a challenging project – cloning the gene for the enzyme glucokinase. At the time, it was known that glucokinase was important for the metabolism of glucose, the sugar that climbs dangerously high in the blood of patients with diabetes. The cloning project was a success, and now, with the work by Hoffman-La Roche, glucokinase is taking center stage as a new drug target for type 2 diabetes.

"There have not been that many new drugs for the treatment of diabetes ever discovered, and this one is unique in its mechanism of action," said Magnuson, assistant vice chancellor for Research and a co-author of the report. "By turning on glucokinase, this novel compound improves insulin secretion by the pancreas and stimulates glucose usage by the liver, both of which are abnormal in diabetes." Magnuson cautions that it's too early to tell what the real value of a glucokinase-activating drug might be. Clinical trials are still in the planning stage. "It has dramatic effects in animals, suggesting it has the potential to be a very powerful new drug," he said.

The promise of such a drug comes from its target, glucokinase. This enzyme – a "glucose sensor" – plays a key role in maintaining sugar balance in the body. It acts mainly in the pancreatic beta cell, where it is important for insulin secretion, and in the liver, where it participates in how glucose is used and stored. Because both insulin secretion and glucose utilization by the liver are defective in patients with diabetes, a single drug that improves both functions is an attractive possibility, Magnuson said.

In the years since they cloned the glucokinase gene, Magnuson and Dr. Daryl K. Granner, director of the Vanderbilt Diabetes Center – joined by several other Vanderbilt laboratories along the way – have ferreted out nuances of how the enzyme works. Most recently, Magnuson and colleagues have genetically engineered mice that lack glucokinase only in selected tissues, like the beta cell or liver, to understand tissue-specific roles and regulation.

"Studies performed at Vanderbilt were essential for demonstrating the importance of this enzyme," Magnuson said.

After the glucokinase gene was cloned, other investigators identified mutations in the human gene. Mutations that cause the enzyme not to function properly have been linked to a form of diabetes called maturity-onset diabetes of the young type 2 (MODY2). And mutations that activate glucokinase – much like the newly discovered compound – cause persistent hyperinsulinemic hypoglycemia of infancy, a condition characterized by high insulin and low blood glucose. These observations solidified the view that glucokinase would be an ideal target for an antidiabetic drug, Magnuson said.

Even so, he added, "no one ever thought we would find a drug that directly targets the enzyme and activates it." The investigators at Hoffman-La Roche were actually screening for compounds that would work in an indirect way to alter glucokinase activity when they found the chemical described in the Science report.

"It was a serendipitous discovery," Magnuson said. "One compound in one of their chemical libraries (of over 120,000 compounds) happened to bind to and activate glucokinase." Other companies that have also been searching for compounds to affect glucokinase activity have not been so fortunate, he said.

The Hoffman-La Roche team demonstrated that the new compound enhances insulin release from isolated rat pancreatic islets. It also lowers blood glucose levels and improves results of oral glucose tolerance tests in rats and mice with diabetes.

Though it will be several more years before clinical trials begin to reveal whether or not drugs based on this compound are effective therapies for diabetes, Magnuson marvels at the progress that's been made since the glucokinase cloning project first got started.

"It really emphasizes the value of basic science research, and how studying enzymes and the mechanisms for regulation of blood glucose can yield important clues and unpredicted things that pay out over time," he said. "Now we're beginning to see the promise of some very basic science research that was done here at Vanderbilt."



Post a Comment

Featured Products From the ProHealth Store
FibroSleep™ Optimized Curcumin Longvida® Energy NADH™ 12.5mg


Article Comments



Be the first to comment on this article!

Post a Comment


 
Optimized Curcumin Longvida with Omega-3

Featured Products

Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function

Natural Remedies

Strontium - The Missing Mineral for Strong Bones Strontium - The Missing Mineral for Strong Bones
Reversing Neurodegeneration with a New Magnesium Compound Reversing Neurodegeneration with a New Magnesium Compound
Milk Thistle: Trusted Support for Health & Healing in a Toxic World Milk Thistle: Trusted Support for Health & Healing in a Toxic World
Everything You Always Wanted to Know About Sleep But Were Too Tired to Ask Everything You Always Wanted to Know About Sleep But Were Too Tired to Ask
The Cellular Enzyme That Promotes Longevity And Reduces Fat Storage The Cellular Enzyme That Promotes Longevity And Reduces Fat Storage

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map